Evidence map›Paper›PMID 40651390›Full record

ReviewEuropean journal of cancer (Oxford, England : 1990)2025

Prioritization of novel agents for further investigation in pediatric non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children's Oncology Group.

Jacquelyn N Crane, David P Douglass, Sapna Oberoi, Natalie B Collins, Ajay Gupta, Jonathan L Metts, Viswatej Avutu, Filemon S Dela Cruz, Jessica L Davis, Noah C Federman and 12 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European journal of cancer (Oxford, England : 1990), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jacquelyn N CraneDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Children's Hospital of Philadelphia, Philadelphia, PA, USA, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: cranej2@chop.edu.
David P DouglassArkansas Children's Hospital, Little Rock, AR, USA; Department of Pediatrics, Division of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Electronic address: DPDouglass@uams.edu.
Sapna OberoiDepartment of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada; Department of Pediatric Hematology/Oncology, Cancer Care Manitoba, Winnipeg, Manitoba, Canada, University of Manitoba, Winnipeg, Manitoba, Canada. Electronic address: soberoi@cancercare.mb.ca.
Natalie B CollinsHarvard Medical School, Boston, MA, USA; Dana-Farber/Boston Children's Cancer and Blood Disorders Center Boston, Boston, MA, USA. Electronic address: natalie_collins@dfci.harvard.edu.
Ajay GuptaDivision of Pediatric Oncology, Department of Pediatrics, Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA. Electronic address: Ajay.Gupta@RoswellPark.org.
Jonathan L MettsCancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA; Sarcoma Department, Moffitt Cancer Center, Tampa, Florida, USA, Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA. Electronic address: jmetts1@jhmi.edu.
Viswatej AvutuDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: avutuv@mskcc.org.
Filemon S Dela CruzDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: delacrf1@mskcc.org.
Jessica L DavisDepartment of Pathology & Laboratory Medicine, Indiana University, Indianapolis, IN, USA. Electronic address: jld13@iu.edu.
Noah C FedermanDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: NFederman@mednet.ucla.edu.
Susan M HinikerDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA. Electronic address: shiniker@stanford.edu.
Theodore W LaetschDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Children's Hospital of Philadelphia, Philadelphia, PA, USA, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: laetscht@chop.edu.
Corinne M LinardicDepartment of Pharmacology & Cancer Biology, Duke University School of Medicine, Durham, NC, USA; Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA, Duke University School of Medicine, Durham, NC, USA. Electronic address: corinne.linardic@duke.edu.
Fariba NavidDepartment of Pediatrics, Division of Hematology-Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA. Electronic address: fnavid@chla.usc.edu.
Raya SaabDepartment of Pediatrics, Stanford University, Stanford, CA, USA. Electronic address: rsaab@stanford.edu.
David S ShulmanHarvard Medical School, Boston, MA, USA; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA. Electronic address: David_Shulman@dfci.harvard.edu.
Jack F ShernPediatric Oncology Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA. Electronic address: john.shern@nih.gov.
Alice SoragniDepartment of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: alices@mednet.ucla.edu.
Elizabeth A StewartDepartment of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA, St. Jude Children's Research Hospital, Memphis, TN, USA. Electronic address: elizabeth.stewart@stjude.org.
Stephanie TerezakisDepartment of Radiation Oncology, University of Minnesota Medical School, Minneapolis, MN, USA. Electronic address: sterezak@umn.edu.
Brenda J WeigelDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. Electronic address: Brenda.Weigel@stjude.org.
Aaron R WeissDepartment of Pediatrics, MaineHealth Maine Medical Center, Portland, ME, USA. Electronic address: Aaron.Weiss@mainehealth.org.

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748NCI NIH HHS U10 CA180886
6 · The paper itself

Abstract

Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) is a group of over 70 tumors that occur across the age range and account for approximately 4 % of childhood cancers. Patients with metastatic or relapsed NRSTS have a dismal prognosis. The histologic, molecular, and clinical heterogeneity of NRSTS and the rarity of individual types pose unique challenges to the study of these diseases. The Children's Oncology Group (COG) Soft Tissue Sarcoma (STS) Committee established a NRSTS Novel Agents Working Group to identify and prioritize agents for further study in pediatric NRSTS, similar to recent efforts in Ewing sarcoma, rhabdomyosarcoma and osteosarcoma. We report the framework that was used to evaluate agents and the results of this evaluation. Immune checkpoint inhibitors and tyrosine kinase inhibitors were identified by the COG STS Committee as candidate classes of agents for inclusion in phase 2 or phase 3 clinical trials of pediatric NRSTS. Gaps in the existing literature and practical barriers were identified for additional classes of agents to guide future drug development efforts.

Indexed as

Antineoplastic AgentsImmune Checkpoint InhibitorsProtein Kinase InhibitorsSarcomaSoft Tissue NeoplasmsChildHumansAntineoplastic AgentsImmune Checkpoint InhibitorsProtein Kinase InhibitorsAntineoplastic AgentsPediatricsSarcoma

Identifiers

PMID40651390
PMCPMC12409922

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.